Frew, Jonathan
Baradaran-Heravi, Alireza
Balgi, Aruna D.
Wu, Xiujuan
Yan, Tyler D.
Arns, Steve
Shidmoossavee, Fahimeh S.
Tan, Jason
Jaquith, James B.
Jansen-West, Karen R.
Lynn, Francis C.
Gao, Fen-Biao
Petrucelli, Leonard
Feldman, Howard H.
Mackenzie, Ian R.
Roberge, Michel
Nygaard, Haakon B.
Funding for this research was provided by:
Weston Brain Institute (TR150199)
Article History
Received: 14 January 2020
Accepted: 24 February 2020
First Online: 16 March 2020
Ethics approval
: Human tissue acquisition, processing, and cell line generation was approved by the UBC Research Ethics Board. Animal use was approved by the UBC Research Ethics Board.
: No applicable.
: SA is a senior scientist at adMare BioInnovations; FSS is an associate scientist at adMare BioInnovations; JT is an associate scientist at adMare BioInnovations; JBJ is the Principal Consultant for JAQJAM Consulting and Chief Executive Officer of Protaxis Therapeutics Inc.; HHF has service agreements through UCSD for consulting activities with TauRX, Arkuda Therapeutics, Axon Neurosciences, Tau Consortium for Scientific Advisory Board, Roche/Genentech Pharmaceuticals for DMC and DSMB activities; HHF and IRM are co-patent holders, Detecting and Treating Dementia Serial Number 12/3–2691 U.S. Patent No. PCT/US2007/07008. Washington, DC: U.S. Patent and Trademark Office; IRM receives a stipend for activities on the scientific advisory board for Prevail Therapeutics and holds a patent related to treating dementia with <i>GRN</i> mutations.